Issue Date: January 29, 2007
Molecular Insight expands portfolio
Molecular Insight Pharmaceuticals has licensed Onalta, a radiolabeled peptide for the treatment of pancreatic neuroendocrine and carcinoid tumors, from Novartis. Onalta, which has orphan drug status from FDA, has been studied in Phase I and II clinical trials. Earlier this month, Molecular Insight added another radiotherapeutic to its portfolio by licensing Solazed, Bayer Schering Pharma's small molecule labeled with iodine-131 for the treatment of malignant melanoma. Financial terms of the deals were not disclosed, but both include upfront, milestone, and royalty payments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society